Bischoff R, Chaloupka M, Westhofen T, Grimm T, Schlenker B, Weinhold P, Tilki D, Stief C G, Kretschmer A
Urologische Klinik und Poliklinik, Klinikum der Universität München, Marchioninistraße 15, 81377, München, Deutschland.
Martini-Klinik Prostatakarzinomzentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Urologe A. 2019 May;58(5):524-528. doi: 10.1007/s00120-019-0903-8.
In the prostate-specific antigen (PSA) era, most prostate cancers (PCa) are diagnosed in a localized stage and a plethora of therapeutic options are warranted in different clinical settings and disease stages of localized PCa. In the current narrative review, we give an overview of the current controversies in the therapeutic landscape of localized PCa and focus on organ-sparing approaches, percutaneous radiotherapy, brachytherapy as well as retropubic and robot-assisted prostatectomy by summarizing studies that have been published within the last two years.
在前列腺特异性抗原（PSA）时代，大多数前列腺癌（PCa）在局部阶段被诊断出来，在局限性PCa的不同临床环境和疾病阶段有大量的治疗选择。在当前的叙述性综述中，我们概述了局限性PCa治疗领域当前的争议，并通过总结过去两年内发表的研究，重点关注保留器官的方法、经皮放疗、近距离放疗以及耻骨后和机器人辅助前列腺切除术。
